Verrica Pharmaceuticals Inc. Additional Paid in Capital, Common Stock
Verrica Pharmaceuticals Inc. (VRCA) had Additional Paid in Capital, Common Stock of $352.05 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $352.05M.
- 2026-03-31: Additional Paid in Capital, Common Stock $350.65M.
- 2025-12-31: Additional Paid in Capital, Common Stock $349.65M.
- 2025-09-30: Additional Paid in Capital, Common Stock $299.80M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $352.05M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $350.65M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $349.65M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $299.80M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $299.08M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $298.18M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $297.17M 10-K · filed 2026-03-11 | $297.16M 10-K · filed 2025-03-11 |
| 2024-09-30 | $256.77M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $254.66M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $252.29M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $250.21M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $248.13M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $236.43M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $234.88M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $203.48M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $202.31M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $174.00M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $172.91M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $171.60M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $170.28M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $168.75M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $166.63M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $136.87M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $130.53M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $128.85M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $127.60M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $126.59M 10-K · filed 2021-03-17 | |
| 2019-09-30 | $125.18M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $124.27M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $123.21M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $122.53M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $123.36M 10-Q · filed 2018-11-07 | |
| 2017-12-31 | $5.39M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |